TargImmune Therapeutics’ CHF 17.7 Million Financing Round

VISCHER has advised TargImmune on the deal.TargImmune Therapeutics has closed its 2021 financing round, raising CHF 17.7m. TargImmune is a private Swiss-based biotechnology firm focused on…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Federica Tiefenthaler

Author: Federica Tiefenthaler

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here